SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 15, 2019
- Accepted in final form October 8, 2019
- First Published December 12, 2019.
Author Disclosures
- Saif Huda, MD, DPhil*,
- Michelangelo Cao, MD, PhD*,
- Anna De Rosa, MD,
- Mark Woodhall, PhD,
- Pedro M. Rodriguez Cruz, MD, DPhil,
- Judith Cossins, DPhil,
- Michelangelo Maestri, MD,
- Roberta Ricciardi, MD,
- Amelia Evoli, MD,
- David Beeson, PhD and
- Angela Vincent, MD, FRCPath, FRS
- Saif Huda, MD, DPhil*,
NONE
NONE
(1) MS Academy, speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) University of Liverpool (2) Walton Centre Foundation Trust
(1) NMO-UK spectrum charity
NONE
NONE
NONE
NONE
NONE
NONE
- Michelangelo Cao, MD, PhD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anna De Rosa, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mark Woodhall, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Pedro M. Rodriguez Cruz, MD, DPhil,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Judith Cossins, DPhil,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michelangelo Maestri, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Roberta Ricciardi, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Amelia Evoli, MD,
scientific advisory board - Alexion data safety monitoring board - UCB
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Scientific award jury member for Grifols
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David Beeson, PhD and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Medical Research Council Programme Grant MR/M006824/1
NONE
Muscular Dystrophy Campaign Grant RA 722
NONE
NONE
NONE
NONE
NONE
NONE
- Angela Vincent, MD, FRCPath, FRS
NONE
NONE
Bial Commercial, Portugal travel and speaker honorarium
Advisory Editorial Board Neurology 2014 - Advisory Editorial Board Annals of Neurology 2018 - Associate Editor for Brain ended 2013
Hold patent with Oxford University for MuSK antibodies and for LGI1/CASPR2 antibodies. Receive a proportion of royalties from these tests.
Royalties for Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010) and for Pittock and Vincent Handbook of Neurology 2017 (Elsevier).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIHR general support for antibody work finished 2016
FNRS honorarium for Prize Panel work £2000 2017
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Clinical Neurosciences (S.H., M.C., M.W., P.M.R.C., J.C., D.B., A.V.), Weatherall Institute of Molecular Medicine and Nuffield, University of Oxford, UK; Department of Clinical and Experimental Medicine (A.D.R., M.M., R.R.), Neurology Unit, Pisa; and Department of Neuroscience (A.E.), Catholic University, Rome, Italy.
- Correspondence
Dr. Vincent angela.vincent{at}ndcn.ox.ac.uk
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
MuSK myasthenia gravis monoclonal antibodiesValency dictates pathogenicityMaartje G. Huijbers, Dana L. Vergoossen, Yvonne E. Fillié-Grijpma et al.Neurology: Neuroimmunology & Neuroinflammation, February 21, 2019 -
Articles
Anti-MuSK autoantibodies block binding of collagen Q to MuSKY. Kawakami, M. Ito, M. Hirayama et al.Neurology, October 19, 2011 -
Editorial
Treating muscle-specific kinase myasthenia gravis from the inside outMaartje G. Huijbers, Jan J.G.M. Verschuuren et al.Neurology: Neuroimmunology & Neuroinflammation, December 12, 2019 -
Editorial
Antibodies to LRP4 and Agrin Are Pathogenic in Myasthenia GravisAt the Junction Where It HappensRobert P. Lisak et al.Neurology, July 07, 2021